Bfsg LLC Buys 790 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Bfsg LLC lifted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 175.6% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,240 shares of the company’s stock after buying an additional 790 shares during the quarter. Bfsg LLC’s holdings in BridgeBio Pharma were worth $31,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. YHB Investment Advisors Inc. purchased a new stake in BridgeBio Pharma in the 1st quarter worth approximately $34,000. Quarry LP bought a new stake in shares of BridgeBio Pharma during the 4th quarter valued at $50,000. EntryPoint Capital LLC purchased a new position in shares of BridgeBio Pharma during the 1st quarter valued at $117,000. Assetmark Inc. boosted its holdings in BridgeBio Pharma by 46.8% in the 4th quarter. Assetmark Inc. now owns 2,931 shares of the company’s stock worth $118,000 after buying an additional 935 shares during the period. Finally, Atria Wealth Solutions Inc. purchased a new stake in BridgeBio Pharma in the 4th quarter worth $214,000. 99.85% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on BBIO. Bank of America dropped their price objective on BridgeBio Pharma from $50.00 to $42.00 and set a “buy” rating for the company in a research note on Tuesday, June 25th. UBS Group cut their price objective on shares of BridgeBio Pharma from $51.00 to $47.00 and set a “buy” rating for the company in a report on Tuesday, May 28th. JPMorgan Chase & Co. lowered their target price on shares of BridgeBio Pharma from $46.00 to $43.00 and set an “overweight” rating on the stock in a report on Wednesday, August 7th. Evercore ISI cut their target price on shares of BridgeBio Pharma from $50.00 to $45.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $70.00 price target on shares of BridgeBio Pharma in a research note on Monday, July 1st. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.09.

BridgeBio Pharma Price Performance

Shares of NASDAQ:BBIO traded up $2.63 during trading on Friday, hitting $27.25. The company had a trading volume of 6,035,059 shares, compared to its average volume of 1,773,382. The stock has a market cap of $5.10 billion, a price-to-earnings ratio of -8.28 and a beta of 1.06. The company has a fifty day simple moving average of $25.65 and a two-hundred day simple moving average of $27.99. BridgeBio Pharma, Inc. has a one year low of $21.62 and a one year high of $44.32.

BridgeBio Pharma (NASDAQ:BBIO) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.61. The company had revenue of $2.17 million during the quarter, compared to the consensus estimate of $3.96 million. The firm’s quarterly revenue was up 32.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.98) earnings per share. On average, equities research analysts anticipate that BridgeBio Pharma, Inc. will post -3.2 earnings per share for the current year.

Insider Transactions at BridgeBio Pharma

In related news, CFO Brian C. Stephenson sold 4,155 shares of the company’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $24.69, for a total transaction of $102,586.95. Following the transaction, the chief financial officer now directly owns 85,192 shares in the company, valued at approximately $2,103,390.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CFO Brian C. Stephenson sold 4,155 shares of the firm’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $24.69, for a total transaction of $102,586.95. Following the completion of the sale, the chief financial officer now directly owns 85,192 shares of the company’s stock, valued at approximately $2,103,390.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Neil Kumar sold 27,389 shares of the company’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $24.69, for a total value of $676,234.41. Following the completion of the transaction, the chief executive officer now directly owns 4,897,443 shares in the company, valued at approximately $120,917,867.67. The disclosure for this sale can be found here. In the last quarter, insiders sold 32,544 shares of company stock worth $807,661. 24.66% of the stock is currently owned by insiders.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.